$1.35 Billion is the total value of EcoR1 Capital, LLC's 49 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 76.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $69,139,000 | +12.5% | 2,721,993 | -18.7% | 5.11% | -20.5% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $58,709,000 | +39.7% | 3,536,684 | -4.2% | 4.34% | -1.3% |
| FATE | Sell | FATE THERAPEUTICS INC | $21,267,000 | -59.1% | 619,855 | -73.5% | 1.57% | -71.1% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $6,563,000 | -52.0% | 135,413 | -58.2% | 0.48% | -66.1% |
| PRVL | Sell | PREVAIL THERAPEUTICS INC | $5,472,000 | -80.0% | 367,218 | -83.7% | 0.40% | -85.9% |
| XCUR | Sell | EXICURE INC | $4,083,000 | -2.9% | 1,673,301 | -41.1% | 0.30% | -31.2% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,481,000 | +14.3% | 1,531,312 | -26.6% | 0.18% | -19.4% |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -1,101 | -100.0% | -0.00% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -6,269 | -100.0% | -0.01% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INC | $0 | – | -264,166 | -100.0% | -0.06% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -13,946 | -100.0% | -0.08% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -1,886,812 | -100.0% | -0.09% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -291,997 | -100.0% | -0.12% | – | |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -30,510 | -100.0% | -0.14% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -41,407 | -100.0% | -0.15% | – |
| CHMA | Exit | CHIASMA INC | $0 | – | -1,512,627 | -100.0% | -0.58% | – |
| VSTM | Exit | VERASTEM INC | $0 | – | -3,255,813 | -100.0% | -0.90% | – |
| ZIOP | Exit | ZIOPHARM ONCOLOGY INC | $0 | – | -3,750,000 | -100.0% | -0.96% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -270,418 | -100.0% | -0.97% | – |
| IONS | Exit | IONIS PHARMACEUTICALS INC | $0 | – | -208,609 | -100.0% | -1.03% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -4,597,701 | -100.0% | -1.16% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -1,249,611 | -100.0% | -1.21% | – |
| GMAB | Exit | GENMAB A/Ssponsored ads | $0 | – | -653,981 | -100.0% | -1.45% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -2,308,079 | -100.0% | -1.54% | – |
| MRUS | Exit | MERUS N V | $0 | – | -1,715,962 | -100.0% | -2.17% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -2,536,156 | -100.0% | -2.24% | – |
| IPHA | Exit | INNATE PHARMA S Asponsored ads | $0 | – | -4,465,668 | -100.0% | -3.12% | – |
| FGEN | Exit | FIBROGEN INC | $0 | – | -882,138 | -100.0% | -3.20% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -4,393,236 | -100.0% | -4.63% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -1,528,031 | -100.0% | -6.43% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.